Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.43 |
| ▸ | SCN1A | P35498 | 2/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27188843 | 1.00 | ABL1 (0.46) | ABL1SCN3AROCK2ROCK1EPHX2 | |
| SCHEMBL23143269 | 0.88 | ROCK2 (0.47) | ABL1SCN3AROCK2ROCK1EPHX2 | |
| SCHEMBL29896087 | 0.88 | ROCK2 (0.47) | ABL1SCN3AROCK2ROCK1EPHX2 | |
| SCHEMBL27188856 | 0.84 | ROCK2 (0.49) | ABL1SCN3AROCK2ROCK1EPHX2 | |
| SCHEMBL29896155 | 0.84 | ROCK2 (0.49) | ABL1SCN3AROCK2ROCK1EPHX2 | |
| SCHEMBL27188815 | 0.81 | ROCK2 (0.50) | ABL1SCN3AROCK2ROCK1PPARG | |
| SCHEMBL29896178 | 0.81 | ROCK2 (0.50) | ABL1SCN3AROCK2ROCK1PPARG | |
| SCHEMBL21407537 | 0.78 | ROCK2 (0.42) | ABL1SCN3AROCK2ROCK1EPHX2 | |
| SCHEMBL30500773 | 0.78 | ROCK2 (0.42) | ABL1SCN3AROCK2ROCK1EPHX2 | |
| SCHEMBL27188851 | 0.78 | ROCK2 (0.47) | ABL1SCN3AROCK2ROCK1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952344-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340527-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2A, GRIN2B | ABL1 4717/4885SCN3A 43/4885ROCK2 4595/4885 |
| US-11952344-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2A, GRIN2B | ABL1 4717/4885SCN3A 43/4885ROCK2 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.